1601 - 1625 of 9104 Results
Title
Year
-
OPENTitle: Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson’s disease and dementia with Lewy bodiesJournal Name: Acta Neuropathologica CommunicationsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page: 4End Page: 4Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s40478-023-01711-wBest OA location URL: https://actaneurocomms.biomedcentral.com/counter/pdf/10.1186/s40478-023-01711-wCitation Count: 41
-
OPENTitle: Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic EfficacyJournal Name: ACS Pharmacology & Translational SciencePublisher: American Chemical Society (ACS)Vol: 4Issue #: 4Start Page: 1306End Page: 1321Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acsptsci.0c00162Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/8369681Citation Count: 30
-
OPENTitle: Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein DestabilizationJournal Name: Molecular NeurobiologyPublisher: Springer Science and Business Media LLCVol: 56Issue #: 8Start Page: 5273End Page: 5286Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s12035-018-1449-2Best OA location URL: https://link.springer.com/content/pdf/10.1007/s12035-018-1449-2.pdfCitation Count: 19
-
OPENTitle: Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR ‐ PSP )Journal Name: Movement Disorders Clinical PracticePublisher: WileyVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mdc3.70672Best OA location URL: https://doi.org/10.1002/mdc3.70672Citation Count: 0
-
OPENTitle: mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cellsJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 12Issue #: 10Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.038596Best OA location URL: https://doi.org/10.1242/dmm.038596Citation Count: 74
-
OPENTitle: Combating Parkinson’s disease-associated toxicity by modulating proteostasisJournal Name: Proceedings of the National Academy of SciencesPublisher: National Academy of SciencesVol: 114Issue #: 5Start Page: 803End Page: 804Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1073/pnas.1620082114Best OA location URL: https://www.pnas.org/content/pnas/114/5/803.full.pdfCitation Count: 6
-
OPENTitle: Feasibility, Safety, and Compliance in a Randomized Controlled Trial of Physical Therapy for Parkinson's DiseaseJournal Name: Parkinson's DiseasePublisher: WileyVol: 2012Issue #:Start Page: 1End Page: 8Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1155/2012/795294Best OA location URL: https://downloads.hindawi.com/journals/pd/2012/795294.pdfCitation Count: 33
-
OPENTitle: Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson’s diseaseJournal Name: Molecular Systems BiologyPublisher: Springer Science and Business Media LLCVol: 22Issue #: 5Start Page: 712End Page: 737Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s44320-026-00190-0Best OA location URL: https://link.springer.com/content/pdf/10.1038/s44320-026-00190-0.pdfCitation Count: 2
- Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial2025OPENTitle: Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized TrialJournal Name: Movement DisordersPublisher: WileyVol: 40Issue #: 12Start Page: 2688End Page: 2699Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/mds.70028Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.70028Citation Count: 5
-
OPENTitle: Differential cardiopulmonary monitoring system for artifact-canceled physiological tracking of athletes, workers, and COVID-19 patientsJournal Name: Science AdvancesPublisher: American Association for the Advancement of Science (AAAS)Vol: 7Issue #: 20Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1126/sciadv.abg3092Best OA location URL: https://doi.org/10.1126/sciadv.abg3092Citation Count: 112
-
OPENTitle: fMRI-based deep brain stimulation programming for Parkinson's disease: a blinded, crossover clinical trialJournal Name: Brain StimulationPublisher: Elsevier BVVol: 19Issue #: 2Start Page: 103069End Page: 103069Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.brs.2026.103069Best OA location URL: https://www.brainstimjrnl.com/article/S1935-861X(26)00046-X/pdfCitation Count: 1
-
OPENTitle: Excess risk of fracture in incident Parkinson’s disease Medicare beneficiariesJournal Name: Injury EpidemiologyPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page: 4End Page: 4Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1186/s40621-025-00643-4Best OA location URL: https://link.springer.com/content/pdf/10.1186/s40621-025-00643-4.pdfCitation Count: 0
-
OPENTitle: The “Michael Foundation”—A foundation against epilepsyJournal Name: EpilepsiaPublisher: WileyVol: 55Issue #: 6Start Page: 803End Page: 805Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1111/epi.12509Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.12509Citation Count: 0
- Disease-modifying therapies for Parkinson's disease2013OPENTitle: Disease-modifying therapies for Parkinson's diseaseJournal Name: The Biomedical & Life Sciences CollectionPublisher: Henry Stewart TalksVol: 2013Issue #: 3Start Page: e1003178End Page: e1003178Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.69645/krxj9755Citation Count: 0
- Fox Trial Finder, un nouvel outil pour la recherche clinique2014RESTRICTEDTitle: Fox Trial Finder, un nouvel outil pour la recherche cliniqueJournal Name: Revue NeurologiquePublisher: Elsevier BVVol: 170Issue #:Start Page: A133End Page: A134Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurol.2014.01.360Citation Count: 0
- P1‐021: Diurnal and intersubject variability of cerebrospinal fluid biomarkers, Aβ‐40/42, alpha‐synuclein and DJ‐1 in healthy volunteers2012RESTRICTEDTitle: P1‐021: Diurnal and intersubject variability of cerebrospinal fluid biomarkers, Aβ‐40/42, alpha‐synuclein and DJ‐1 in healthy volunteersJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 8Issue #: 4S_Part_3Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jalz.2012.05.296Citation Count: 0
- No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187)2013RESTRICTEDTitle: No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 80Issue #: 7_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.80.7_supplement.p04.187Citation Count: 0
- O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH2018RESTRICTEDTitle: O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACHJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 14Issue #: 7S_Part_11Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jalz.2018.06.2691Citation Count: 0
-
OPENTitle: Reply to Comment on: The Most Bothersome Aspects of off Periods Reported by Individuals with Parkinson's DiseaseJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 7Issue #: 7Start Page: 879End Page: 880Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13021Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7533975Citation Count: 0
-
OPENTitle: Abstract #81: Improving Neurostimulation Clinical Trial Design with Patient Experience DataJournal Name: Brain StimulationPublisher: Elsevier BVVol: 12Issue #: 2Start Page: e28End Page: e29Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2018.12.088Best OA location URL: https://doaj.org/article/33431349c85d454db7ad2af33222a015Citation Count: 0
- Automatic Scoring of Parkinson’s Disease Motor Symptoms Using a Smartwatch (P2.8-001)2019RESTRICTEDTitle: Automatic Scoring of Parkinson’s Disease Motor Symptoms Using a Smartwatch (P2.8-001)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 92Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.92.15_supplement.p2.8-001Citation Count: 0
- Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)2014RESTRICTEDTitle: Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 82Issue #: 10_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.82.10_supplement.p1.016Citation Count: 0
- Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): Initiation of a Long-Term Observational Study (P2.8-011)2019RESTRICTEDTitle: Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): Initiation of a Long-Term Observational Study (P2.8-011)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 92Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.92.15_supplement.p2.8-011Citation Count: 0
- α4β2 * Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance Disorders2021OPENTitle: α4β2 * Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance DisordersJournal Name: Annals of NeurologyPublisher: WileyVol: 90Issue #: 1Start Page: 130End Page: 142Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ana.26102Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.26102Citation Count: 25
- Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study (P4.007)2017RESTRICTEDTitle: Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study (P4.007)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 88Issue #: 16_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.88.16_supplement.p4.007Citation Count: 0